Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label obefazimod follow-up in ulcerative colitis
2023-507974-42-00Phase 2Authorised
- Sponsor
- Abivax
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of obefazimod in autoimmune colitis, sponsored by Abivax. Primary endpoint: Number of adverse events. Planned start Dec 2021; status: authorised.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-507974-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507974-42-00.